Resilient first half at life science company
Life sciences group, ProBiotix Health has revealed a ‘resilient’ first half will losses narrowing and turnover rising sharply at the Wakefield based company.
In the six months to 30 June, ProBiotix Health, which specialises in cardiometabolic probiotics, said revenue rose by 33% to £1.34m on the same period last year, while gross profit also increased by 33% to £748,000.
The company cut its EBITDA loss by more than half to £112,000 in the first half of last year.
International expansion was a key driver, with sales outside the US jumping 127% to £584,000 from £257,000. The group also strengthened its cash position, ending the half year with £1.3m on hand compared with £865,000 a year earlier.
Steen Andersen, CEO of ProBiotix Health, said: “We are pleased with the progress that has been achieved in the first half of 2025, which has resulted in another record performance. The increasing consumer awareness and market focus on preventive cardiometabolic supplement products continues to expand at an impressive pace, reflecting the growing demand for effective, science-backed health solutions.
“We remain committed to executing the growth strategy to deliver sustainable value for shareholders and look forward to reporting further on our progress.”
For more information and the source, visit: Resilient first half at life science company | TheBusinessDesk.com